🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchClinicalTrials.gov GLP-1 trial tracker — updated weekly Page 18

ClinicalTrials.gov GLP-1 trial tracker — updated weekly

TrialTracker_MD Mon, Feb 26, 2024 at 4:00 PM 411 replies 11,865 viewsPage 18 of 20
B12Beth
Member
289
890
Oct 2024
Maryland
Sep 10, 2025 at 4:08 AM#86

Following on from NurseKim_ATL — and this may be the naive question:

How long did you give it before you decided it was working?

Last edited: Sep 10, 2025 at 7:08 AM
19 17GraceAZ_72, carl_compliance, DanielChem_CHI and 16 others
Reply Quote Save Share Report
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Sep 18, 2025 at 3:27 AM#87
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. This treats a plausible mechanism as a demonstrated one. Plausible is where you start looking, not where you stop.

20 18PharmD_Rodriguez, julia.endo, JessicaM_2024 and 17 others
Reply Quote Save Share Report
PharmHunterJen
Member
567
2,345
Jul 2024
Illinois
Sep 26, 2025 at 2:42 AM#88
LabKate said:
If you are going to change something, change one thing and give it long enough to express itself.

Agreed, and one caution: a single measurement is not a measurement. Anything that moves day to day needs a trend before it means anything at all.

Ask again with the specifics and you will get a better answer than this one.

21 19kevin_tulsa, Dr.PainCLE, mike_mealprep and 18 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Admin
Administrator
2,456
9,812
Oct 2023
Online
Oct 4, 2025 at 1:52 AM#89

Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful.

22 20BiostatsBrad, PeptideSynthNJ, Dr.KarenChen and 19 others
Reply Quote Save Share Report
LipidDoc_ATL
Senior Member
1,123
5,678
Apr 2024
Atlanta, GA
Oct 12, 2025 at 12:58 AM#90

This was answered several pages up and is worth repeating rather than re-litigating:

I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

44 17KristenIndy, MarkLI_maint, Dr.PeteFamMed and 41 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register